Bioavailability (BA) and bioequivalence (BE) studies play a major role in the drug development phase for both new drug products and their generic equivalents, and thus attract considerable attention globally. BE is a strategy to introduce generic equivalents of brand-name drugs (innovator drugs) to lower the cost of medication through proper assessment as directed by the international regulatory authorities. There are several approaches to assess BE and each regulatory authority has its own regulations/guidance for conducting BA/BE studies before approving generic products for marketing in their country. Therefore, a thorough understanding is required of these BA/BE concepts and basic regulatory considerations for conducting BA/BE studies. This article briefly reviews the BA/BE concepts, approaches, designs, and various basic regulatory considerations and prospects for conducting BA/BE studies.
Introduction
Life expectancy of patients has increased globally during the last three decades due to the new drug discovery (brand-name drugs) as well as generic drug production. It is well known that most health care interventions occur through medication. The rising cost of medication has been contributing to the total overall cost of health care and thus receives considerable attention globally. A major strategy for lowering the cost of medication, and thereby reducing its contribution to total health care costs, has been the introduction of generic equivalents of brand-name drugs (innovator drugs). 1 This strategy has been effective in reducing total prescription cost by 11% without sacrificing quality. 2 Generic drugs have captured more than 65% of the global market and account for 66% of prescriptions filled in the United States but for less than 13% of the cost. 3 Thus, because of the importance of generic drugs in health care, it is imperative that the pharmaceutical quality, safety, and efficacy of generics should be reliably compared with the corresponding innovator drugs (brand-name drugs). The US Food and Drug Administration (FDA) publishes a list of drug products and equivalents, Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the "Orange Book". The FDA's designation of "therapeutic equivalence" indicates that the generic formulation is (among other things) bioequivalent to the innovator formulation and signifies the FDA's expectation that the formulations are likely "to have equivalent clinical effect and no difference in their potential for adverse effects". 4 The assessment of "interchangeability" between the innovator and generic Documented bioequivalence = Therapeutic equivalence Mastan et al products is carried out by a study of "in vivo equivalence" or "bioequivalence". 1 The steps involved in the development of a potential generic product are briefly described in Figure 1 . The pertinent situations in which bioequivalence studies are required include i) when the proposed marketed dosage form is different from that used in pivotal clinical trials; ii) when significant changes are made in the manufacture of the marketed formulation; and iii) when a new generic product is tested against the innovator's marketed product. Based on this background, bioavailability (BA) and bioequivalence (BE) information has been determined to have practical and public health value for pharmaceutical industries, regulatory agencies, patients, and practitioners. To understand the basis of the controversy around innovator drug and generic
A snapshot on historical perspective
The concepts of BA and BE have gained considerable importance during the last three decades and have become the cornerstones for the approval of brand-name and generic drugs globally. Consequently regulatory authorities also started developing and formulating regulatory requirements for approval of generic drug products. It is encouraging to know that efforts by regulatory authorities and the scientific community at national as well as international levels are continuing, in order to understand and develop more efficient and scientifically valid approaches to assess BE of various dosage forms, including some of the complex special dosage forms. Using the BE as the basis for approving generic drugs was established by the Drug Price Competition and Patent Restoration Act of 1984 (Hatch-Waxman Act). Subsequently various criteria and approaches for conducting and r eporting BE studies for generic products from various r egulatory authorities have been progressing. Table 1 presents a brief historical overview of FDA activities with respect to BA/BE studies.
Hatch-waxman Act 10
The Hatch-Waxman Act was an attempt to resolve two major issues: 1) regulatory delays in marketing of pharmaceutical products faced by innovator (also called pioneer or research) drug companies and 2) difficulties generic drug companies had at that time in marketing generic versions of pioneer products following expiry of pertinent patent(s). 11, 12 In practical terms, this Act made the following three important provisions: 1) it provided for the extension of the term of one existing patent for innovator drugs; 2) it made provisions for the marketing of generic versions of patented drugs on the day after patent expiry; and 3) it provided opportunities to challenge the validity of patents issued to innovator drug companies.
Regulatory authorities, regulatory aspects, and international efforts to harmonize approaches to bioequivalence assessment
Due to significant recognition of the BA/BE concept all over the world, tremendous advancements have been made by the FDA as well as various national, international, and supranational regulatory authorities. In parallel, pharmaceutical industry and academia are also contributing exclusively in the area of assessment of BE. Currently available approaches to determine BE of generic products are largely standardized due to discussion and consensus reached among various stakeholders at numerous national and international meetings, conferences, and workshops (eg, American Association of Pharmaceutical Scientists, Federation Internationale Pharmaceutique). Thus the currently available excellent scientific and regulatory guidance documents are due to the combined efforts of industry, academia, and regulatory scientists.
Every country now has its own individual regulatory authority as well as regulatory guidance for BA/BE studies, and the magnitude of assessment of BE of drug product is influenced by the regulatory environment of the respective country of marketing. The regulatory authorities of various countries and international organizations are listed and briefly described in Table 2 . In the United States, the FDA approves and grants marketing authorization of generic drugs by applying the regulatory requirements provided in the Code of Federal Regulations (CFR). Table 3 Table 1 A brief historical overview of Food and Drug Administration activities with respect to BA/BE studies 8, 9 Year Activity 
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The basic regulatory considerations for BA/BE studies some of the relevant sections in the CFR related to BA/BE. The magnitude of regulatory influence is often dictated by the availability of resources, expertise, and lack of regulation or its implementation. Thus there is a greater need to harmonize the regulatory environment globally for BE assessment as far as practicable so that the drug product marketed in different parts and regions of the world would have optimum drug product quality in terms of interchangeability. In the recent years, some significant progress has been made towards harmonization; in addition some regulatory authorities are also in the process of cooperating with their counterparts from other countries to harmonize the regulatory requirements while streamlining their own regulatory requirements.
Tremendous work towards harmonization was initiated and completed by some organizations, especially the International Conference on Harmonization (ICH) and the World Health Organization (WHO). ICH is a consortium of regulatory authorities from Europe, Japan, and the United States which focused primarily on developing guidelines for standardizing and harmonizing the regulatory requirements, mainly for aspects of chemistry and manufacturing control, safety, and efficacy of new drug product quality. In addition, it developed specific documents for the content and format of drug product dossiers. It has not yet focused on harmonizing the requirements for approval of generic equivalents. On the other hand, the WHO has made remarkable progress specifically in developing international consensus on the regulatory requirements for assessing BE for marketing authorization of multisource pharmaceutical products for interchangeability, selection of comparator product for BE assessment, and other related regulatory documents. Apart from the ICH and WHO other European and Asian organizations (national and i nternational) are actively involved in harmonization efforts for assessing of BE and improving the quality of pharmaceutical products globally.
Assessment of bioequivalence 14-25
The assessment of BE of different drug products is based on the fundamental assumption that two products are equivalent when the rate and extent of absorption of the test/generic drug does not show a significant difference from the rate and extent of absorption of the reference/brand drug under similar experimental conditions as defined. As per the different regulatory authorities, BE studies are generally classified as: 1. Pharmacokinetic endpoint studies. 2. Pharmacodynamic endpoint studies. 3. Clinical endpoint studies. 4. In vitro endpoint studies.
The general descending order of preference of these studies includes pharmacokinetic, pharmacodynamic, clinical, and in vitro studies. 14 
Pharmacokinetic endpoint studies
These studies are most widely preferred to assess BE for drug products, where drug level can be determined in an easily accessible biological fluid (such as plasma, blood, urine) and drug level is correlated with the clinical effect. The statutory definition of BA and BE, expressed in rate and extent of absorption of the active moiety or ingredient to the site of action, emphasizes the use of pharmacokinetic measures to indicate release of the drug substance from the drug product with absorption into the systemic circulation. Regulatory guidance recommends that measures of systemic exposure be used to reflect clinically important differences between test and reference products in BA and BE studies. 14 These measures include i) total exposure (AUC 0-t or AUC 0-∞ for single-dose studies and AUC 0-τ for steady-state studies), ii) peak exposure (C max ), and iii) early exposure (partial AUC to peak time of the reference product for an immediate-release drug product). Reliance on systemic exposure measures will reflect comparable rate and extent of absorption, which, in turn, will achieve the underlying goal of assuring comparable therapeutic effects. Single dose studies to document BE were preferred because they are generally more sensitive in assessing in vivo release of the drug substance from the drug product when compared to multiple dose studies. Table 4 describes the general pharmacokinetic parameters (primary and secondary) for single-dose, multiple-dose, and urinary data.
The following are the circumstances that demand multiple -dose study/steady state pharmacokinetics: 15, 16, 18, [21] [22] [23] [24] [25] [26] • Dose-or time-dependent pharmacokinetics.
• For modified-release products for which the fluctuation in plasma concentration over a dosage interval at steady state needs to be assessed. • If problems of sensitivity preclude sufficiently precise plasma concentration measurements after single-dose administration. • If the intra-individual variability in the plasma concentration or disposition precludes the possibility of demonstrating BE in a reasonably sized single-dose study and this variability is reduced at steady state. • When a single-dose study cannot be conducted in healthy volunteers due to tolerability reasons, and a single-dose study is not feasible in patients. • If the medicine has a long terminal elimination half-life, and blood concentrations after a single dose cannot be followed for a sufficient time. • For those medicines that induce their own metabolism or show large intra-individual variability. • For combination products for which the ratio of plasma concentration of the individual substances is important. • If the medicine is likely to accumulate in the body.
• For enteric coated preparations in which the coating is innovative.
Under normal circumstances, blood should be the biological fluid sampled to measure drug concentrations. Most drugs may be measured in serum or plasma; however, in some drugs, whole blood (eg, tacrolimus) may be more appropriate for analysis. If the blood concentrations are too minute to be detected and a substantial amount (.40%) of the drug is eliminated unchanged in the urine, the urine may serve as the biological fluid to be sampled (eg, alendronic acid). 21, 22, 26 Pharmacodynamic endpoint studies 1, 15 Pharmacokinetic studies measure systemic exposure but are generally inappropriate to document local delivery BA and BE. In such cases, BA may be measured, and BE may be established, based on a pharmacodynamic study, providing an appropriate 
21CFR section
Type of provision/information 21CFR 314.94(a)(9) Chemistry, manufacturing, and controls; permitted changes in inactive ingredients for parenteral, otic, ophthalmic, and topical drug products 21CFR 320. 1 Definitions of bioavailability, pharmaceutical equivalents, pharmaceutical alternatives, and bioequivalence 21CFR 320. 21 Regulatory requirements related to submission of in vivo bioavailability and bioequivalence data 21CFR 320. 22 Criteria for waiver of evidence of in vivo bioavailability or bioequivalence data 21CFR 320. 23 Basis for measuring in vivo bioavailability or demonstrating bioequivalence 21CFR 320. 24 Types of evidence to measure bioavailability or establish bioequivalence 21CFR 320. 25 Guidelines for the conduct of an in vivo bioavailability study 21CFR 320. 26 Guidelines on the design of a single dose in vivo bioavailability or bioequivalence study 21CFR 320. 27 Guidelines on the design of a multiple-dose in vivo bioavailability study 21CFR 320. 28 Correlation of bioavailability with an acute pharmacological effect or clinical evidence 21CFR 320. 29 Analytical methods for an in vivo bioavailability or bioequivalence study 21CFR 320. 30 inquiries regarding bioavailability and bioequivalence requirements and review of protocols by the FDA 21CFR 320. 32 Procedures for establishing or amending a bioequivalence requirement 21CFR 320. 33 Criteria and evidence to assess actual or potential bioequivalence problems 21CFR 320. 36 Requirements for maintenance of records of bioequivalence testing 21CFR 320. 38 Retention of bioavailability samples 21CFR 320.63
Retention of bioequivalence samples pharmacodynamic endpoint is available. Pharmacodynamic evaluation is measurement of the effect on a pathophysiological process, such as a function of time, after administration of two different products to serve as a basis for BE assessment. Regulatory authorities request justification from the applicant for the use of pharmacodynamic effects/parameters for the establishment of BE criteria. These studies generally become necessary under two conditions 1) if the drug and/or metabolite(s) in plasma or urine cannot be analyzed quantitatively with sufficient accuracy and sensitivity; 2) if drug concentration measurement cannot be used as surrogate endpoints for the demonstration of efficacy and safety of the particular pharmaceutical product. The other important specifications for pharmacodynamic studies include i) a dose-response relationship should be demonstrated; ii) sufficient measurements should be taken to provide an appropriate pharmacodynamic response profile; iii) the complete dose-effect curve should remain below the maximum physiological response; iv) all pharmacodynamic measurements/methods should be validated for specificity, accuracy, and reproducibility. Examples of these pharmacodynamic studies include locally acting drug products and oral inhalation drug products, such as metered dose inhalers and dry powder inhalers, and topically applied dermatologic drug products, such as creams and ointments. Bronchodilator drug products, such as albuterol metered dose inhalers, produce relaxation of smooth muscle of the airways. For these drug products, a pharmacodynamic endpoint, based either on increase in forced expiratory volume in 1 second (FEV 1 ) or on measurement of PD20 or PC20 (the dose or concentration, respectively, of a challenge agent) is clinically relevant and may be used for BA and BE studies. 27, 28 Clinical endpoint studies or comparative clinical trials
In the absence of pharmacokinetic and pharmacodynamic approaches, adequate and well-controlled clinical trials may be used to establish BA/BE. Several international regulatory authorities provide general information about the conduct of clinical studies to establish BE.
in vitro endpoint studies
More recently, a Biopharmaceutics Classification System (BCS) has categorized drug substances as having either high or low solubility and permeability and drug products as exhibiting rapid dissolution. 29 According to this approach, drug substances may be classified into four primary groups: 1) highly soluble and highly permeable; 2) highly permeable and poorly soluble; 3) highly soluble and poorly permeable; 4) poorly soluble and poorly permeable. Using this BCS approach, a highly permeable, highly soluble drug substance formulated into a rapidly dissolving drug product may need only in vitro dissolution studies to establish BE. 20 In addition, in vitro approaches to document BE for nonbioproblem drugs approved before 1962 remain acceptable as per FDA regulations. Dissolution tests can also be used to reduce the number of in vivo studies in other circumstances, and to i) assess batch-to-batch quality and support batch release; ii) provide process control and quality assurance; and iii) assess the need for further BE studies relative to minor post-approval changes, where they function as a signal of bioinequivalence. 20 The broad spectrum of BA/BE in vitro studies specifications were provided by each regulatory authority.
General regulatory considerations for BA/BE studies
The processes of study design and workflow of BA/BE studies are presented in brief in Figures 2 and 3 , respectively. The general considerations for the advancement of conducting BA/BE studies are:
• Study design and protocol.
• Bioanalysis.
• Selection of appropriate analyte(s).
• BE metrics and data treatment.
• Statistical approaches and analysis. Single dose C max , AUC 0-t , AUC 0-∞ T max , AUC % extrapolation, MRT, K el , and T 1/2 Steady state C max(ss) , C min(ss) , AUC 0-τ T min(ss) , T max(ss) , C avg , % swing, % fluctuation Urinary based Ae (0-t) , Ae (0-∞) , R max T lag Notes: C max , Maximum plasma concentration; C min , Minimum plasma concentration; C max(ss) , Maximum plasma concentration at steady-state; C min(ss) , Minimum plasma concentration at steady-state; C avg , Average plasma concentration; T max , Time to C max , AUC 0-t , Area under the plasma/serum/blood concentration-time curve from time zero to time t where t is the last time point with measurable concentration; AUC 0-∞ , Area under the plasma/serum/blood concentration-time curve from time zero to time infinity; AUC 0-τ , AUC during a dosage interval at steady state; MRT, Mean residence time; Ae (0-t) , Cumulative urinary excretion from pharmaceutical product administration until time t; Ae (0-∞) , Amount of unchanged API excreted in the urine at infinite time (7-10 half-lives); T 1/2 , Plasma concentration elimination half-life; % fluctuation, (C max(ss) -C min(ss) )/C avg ⋅100; % swing, (C max(ss) -C min(ss) )/C min ⋅100. Abbreviation: APi, active pharmaceutical ingredient; Rmax, maximum rate of excretion or release rate; Tlag, lag time. 
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The basic regulatory considerations for BA/BE studies on within-subject variability for both test and reference product or parallel design) can adequately address the question at hand; standardization of the environmental conditions (such as, fasting, fed, ambulatory, supine); and ensuring that good clinical practices are strictly adhered to and documented. All of these should be planned a priori and embodied in the overall protocol and study plan for the smooth execution of BE studies.
Generally the study design and number of studies (singledose and/or multiple-dose and/or fasting and/or fed) depend on the RLD or reference product, physico-chemical properties of the drug, its pharmacokinetic properties, and proportionality in composition with justification along with respective regulatory guidance and specifications. Table 5 describes various study designs generally used for BA/BE studies.
Genetic variations among ethnic and/or racial background can alter the drug disposition (eg, white persons who predominantly express less P-glycoprotein in intestinal epithelial cells than black persons) and thus lead to potential sources of variability in pharmacokinetic parameters apart from geographical, food habits, and metabolic variations. For BE studies, these problems will be minimized using crossover designs, and hence US and Europe regulatory agencies (but not Japan, Korea, and Mexico, for example.) are accepting BE studies from other countries also, as these factors mostly do not have much effect on test and reference products. BE studies should be generally performed on a healthy population unless safety warranties (patient population should be preferred, if the risk associated with the drug is more in healthy population; eg, anticancer drugs) as they facilitate the provision of adequate information to detect formulation differences and allow extrapolation of this information to populations for which the brand drug is approved.
The regulatory specifications on strength to be investigated, demographics, sample size, number of studies required, fasting and/or fed requirements, standardization of experimental conditions (fluid intake, posture, and physical activity), add on design, and sampling and washout criteria are briefly described in Tables 6-13 . As a result of random variation or a larger than expected relative difference, there is no guarantee that the sample size as calculated will pass the standards. If the study is run with the appropriate size and the standards are not met, the sponsor may add more subjects, and this approach is generally referred to as an "add-on" study (Table 12 ).
Bioanalysis [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [34] [35] [36] In a general prospective of BA/BE studies, bioanalysis should be the subsequent step following clinical operations of the study (as shown in Figure 3 ), and it should be executed with strict adherence to good laboratory practices, standard operating procedures, and specific regulatory requirements. Bioanalysis is a term generally used to describe the quantitative measurement of a compound (drug) or its metabolite in biological fluids, primarily blood, plasma, serum, urine, or tissue extracts. 34 Bioanalysis typically consists of two important components 1) sample preparation and 2) detection of the desired compound using a validated method. Excellent scientific and regulatory guidance documents are available that outline the requirements for a fully validated method. The application of validated methodology presupposes that the most appropriate analyte is monitored to attest to the question of BE.
Selection of appropriate analyte(s)
Each regulatory authority has its own specifications for selection of an appropriate analyte to be measured as well as consideration for BE. Most commonly, the investigator should consult the relevant regulatory agency for guidance on a particular therapeutic agent. The general considerations are discussed in the following sections.
Parent drug vs metabolite(s)
BE based on test/reference comparisons of pharmacokinetic measures serves two purposes 1) to act as a surrogate for therapeutic equivalence, 2) to provide in vivo evidence of pharmaceutical quality. The overall objective of BE is to ensure that generic products have efficacy and safety characteristics similar to those of the corresponding reference product. For the most part, traditional BE studies have been carried out on the basis of measurement of only the parent drug in body fluids such as plasma or serum. In some cases, however, monitoring a metabolite, or the parent and metabolite(s), may be more appropriate. A number of reasons for use of metabolite data have been put forward, 35 such as i) the parent is an inactive prodrug, ii) plasma concentrations of the parent drug are too low to monitor because of inadequate assay sensitivity, iii) the parent drug is metabolized rapidly to an active metabolite, and iv) the parent drug and a metabolite both have therapeutic activities but the metabolite is present in higher concentrations when the parent drug is rapidly and extensively metabolized such that only metabolite(s) data are available. 14 
Enantiomers vs racemates
For BA/BE studies, measurement of both enantiomers may be important. For BE studies, measurement of the racemate using an achiral assay has been recommended, without measurement of individual enantiomers except when 14 i) the enantiomers exhibit different pharmacodynamic characteristics; ii) the enantiomers exhibit different pharmacokinetics; iii) the 
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The basic regulatory considerations for BA/BE studies Table 6 Brief description of the criteria on strength to be investigated in BA/BE studies [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [30] [31] [32] Regulatory authority Linear pharmacokinetics
Nonlinear pharmacokinetics
Europe and Australia General: The bioequivalence study should in general be conducted at the highest strength Highly soluble drug and any safety concern: Lower strength acceptable Problems of sensitivity of the analytical method: Highest strength acceptable For drugs with nonlinear pharmacokinetics characterized by a more than proportional increase in AUC with increasing dose over the therapeutic dose range, the bioequivalence study should in general be conducted at the highest strength. As for drugs with linear pharmacokinetics a lower strength may be justified if the highest strength cannot be administered to healthy volunteers for safety/tolerability reasons. Likewise a higher dose may be used in case of sensitivity problems of the analytical method in line with the recommendations given for products with linear pharmacokinetics above.
For drugs with a less than proportional increase in AUC with increasing dose over the therapeutic dose range, bioequivalence should in most cases be established both at the highest strength and at the lowest strength (or strength in the linear range), ie, in this situation two BE studies are needed.
if the nonlinearity is not caused by limited solubility but is due to, eg, saturation of uptake transporters and provided that a) same manufacturing process; b) qualitative composition of the different strengths is the same; c) composition of the strengths are quantitatively proportional; d) appropriate in vitro dissolution data should confirm the adequacy of waiving additional in vivo BE testing and the test and reference products do not contain any excipients that may affect gastrointestinal motility or transport protein, it is sufficient to demonstrate BE sport proteins at the lowest strength (or strength in the linear range).
United States
Reference listed drug in the Orange Book; usually the highest strength if formulations are proportionally similar For an ANDA, conducting an in vivo study on a strength that is not the highest may be appropriate for reasons of safety, subject to approval by the Division of Bioequivalence, Office of Generic Drugs, and provided that the following conditions are met: a) Linear elimination kinetics has been shown over the therapeutic dose range; b) the higher strengths of the test and reference products are proportionally similar to their corresponding lower strength; c) comparative dissolution testing on the higher strength of the test and reference products is submitted and found to be appropriate
Not specified
Saudi Arabia For conventional solid oral drug products, in vivo BE studies are conducted on the highest strength This requirement for the lower strengths can be waived provided: a) in vivo BE is demonstrated on the highest strengths; b) in vitro dissolution testing is acceptable; and c) the formulation for the lower strengths are proportionally similar to the strength which has undergone in vivo BE testing (ie, the ratio of active ingredients and excipients between the strengths is essentially the same)
Canada Generally use strength with largest sensitivity to identify differences in formulation. Reference product is 1) a drug product that has been issued a notice of compliance pursuant to section C.08.004 of the Food and Drug Regulations, and is currently marketed in Canada by the innovator, or 2) a drug product acceptable to the Director. 
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primary activity resides with the minor enantiomers; and iv) nonlinear absorption is present (as expressed by a change in the enantiomers concentration ratio with change in the input rate of the drug) for at least one of the enantiomers.
Drug products with complex mixtures
Certain drug products may contain complex drug substances, ie, active moiety or active ingredient(s), which are mixtures of multiple synthetic and/or natural source components. Some or all of the components of these complex drug substances may not be characterized by chemical structure and/or biological activity. In this circumstance, BA and BE studies may be based on selected markers of peak and total exposure. 36 BE metrics and data treatment 1, 14, 36 The most frequent data treatment involves analysis of variance using a suitable program such as SAS ® (Statistical Analysis System, SAS Institute, Cary, NC) or WinNonlin ® (Pharsight Corporation, St. Louis, MO) so that contributions from subject, period, product/formulation, and interactions between these can be examined. Geometric mean ratios and log transformed data are examined to test the hypothesis that the 90% confidence interval of extent (AUC 0-t and AUC 0-∞ ) and the maximum concentration (C max ) fall within the acceptance limits of 80% to 125%. More recently, other data treatments have been popular, which include partial area measurements and exposure metrics including C max / AUC, especially with highly variable drugs (HVDs), and with drugs having a long terminal t 1/2 , specialized dosage forms, and/or whose time to C max is considered important (eg, certain analgesics). In all of these cases, the objective has been to err on the side of protecting the consumer while at times increasing risk to the manufacturer. Hence, over the last 15 years, considerable debate has occurred globally about the fundamental scientific rationale used to establish BE for some of these "special" cases, in an effort to solve these issues associated with harmonization of drug equivalence approaches.
Statistical approaches 1,14-26, [35] [36] [37] Considerable debate has ensued over the past 20 years on statistical testing and BE studies. After protracted, wideranging, and in-depth discussion among various experts from different locations, specific statistical regulatory guidance is available to investigators conducting BE studies. The various pharmacokinetic parameters derived from the plasma concentration-time curve are subjected to ANOVA in which the variance is partitioned into components due to 
Nonlinear pharmacokinetics
Asia Test products in an application for a generic product are normally compared with the corresponding dosage form of an innovator medicinal product (reference product). The choice of reference product should be justified by the applicant and agreed upon by the regulatory authority. If the innovator product is not available, an alternative comparator product approved by drug regulatory authority of the country can be used.
New Zealand
When the drug product is the first market entry of that type of dosage form, the reference product should normally be the innovator's prompt-release formulation. The comparison should be between a single dose of the drug formulation and doses of the prompt-release formulation which it is intended to replace.
Korea
Reference drug product is an approved drug product (or an approved imported drug product) the safety and efficacy of which have been established or recognized by the Commissioner of the KFDA. and consequently asked for a retrospective examination of the power of the test of null hypothesis. 37 Adequate statistical approaches should be considered to establish the BE of generic product to that of reference product. Much worldwide discussion and interaction has focused on facilitating the appropriate statistical approaches to establish interchangeability between generic drug and reference drug. The pertinent statistical approaches include i) study power; ii) 75/75 rule; and iii) 90% confidence interval. 1 
Study power
The conduct of a BE study should require some prior knowledge of the performance of the products (generic and brand drugs) in the human body so that an appropriate number of test subjects can be enrolled and provide adequate power to test the hypothesis with a reasonable likelihood (ie, at least 80%) that the two products are indeed bioequivalent. In fact, the alternative hypothesis that two products (generic and brand drugs) are statistically different leads to the conclusion that they are not bioequivalent. The two criteria considered most important to understand are the inherent variability of the drug and the geometric mean ratio between the test and reference product. Both of these parameters can be determined through the conduct of a pilot study (n = 6-12) subjects, periods, and treatments. The classical null hypothesis test is the hypothesis of equal means, H0: µT = µR (ie, products are bioequivalent), where µT and µR represent the expected mean bioavailabilities of the test and reference products, respectively. The alternate hypothesis therefore is H1: µT ≠ µR (ie, products are bioinequivalent). [35] [36] [37] The detection of the difference becomes simply a function of sample size, and since the probable magnitude of the difference is the critical factor, this gives rise to two anomalies: 38 i) a large difference between two formulations which is nevertheless not statistically significant if error variability is high and/or sample size not large enough, ii) a small difference, probably of no therapeutic importance whatsoever, which is shown to be statistically significant if error variability is minimal and/or sample size adequately large.
The first case suggests a lack of sensitivity in the analysis, and the second an excess of it. Consequently, any practice that increases the variability of the study (sloppy design, assay variability, and within-formulation variability) would reduce the chances of finding a significant difference and hence improve the chances of concluding BE. The FDA therefore recognized that a finding of no statistical significance in the first case was not necessarily evidence of BE Generally recommends a number of 24 normal healthy subjects. Should enroll a number of subjects sufficient to ensure adequate statistical results, which is based on the power function of the parametric statistical test procedure applied. The number of subjects should be determined using appropriate methods taking into account the error variance associated with the primary parameters to be studied (as estimated for a pilot experiment, from previous studies or from published data), the significance level desired (α = 0.05), and the deviation from the reference product compatible with BE (±20%) and compatible with safety and efficacy
New Zealand 12
The number of subjects should provide the study with a sufficient statistical power (usually $80%) to detect the allowed difference (usually 20%) between the test and reference medicines for AUC and C max . This number (n) may, in many cases, be estimated in advance from published or pilot study data using formula If the calculated number of subjects appears to be higher than is ethically justifiable, it may be necessary to accept a statistical power which is less than desirable. Normally it is not practical to use more than about 40 subjects in a bioavailability study Mexico Sample size must not be ,24 subjects considering both sequences or it must meet the requirement related to a difference to be detected of ±20% for the reference product's mean, associated with a type-i error (*) of 0.05 and a minimal potency of (1-*) of 0.8 for this kind of design. A sample size of ,24 subjects must be scientifically justified Brazil
The number of healthy volunteers shall all times assure an adequate statistical power to guarantee reliability of BE study results 
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The basic regulatory considerations for BA/BE studies to determine the proper sample size required for the pivotal study to establish BE as well as to minimize the possibility of undersizing the study. 1
75/75 rule
This approach was the first application wherein individual BE (IBE) was being tested. The biomedical community felt that unless the change in the biological system was greater than 20% to 25%, it would really not pose a significant clinical risk of invalidating the use of one therapeutic strategy versus another. This formed the basis for the 75/75 rule, which states that two products are equivalent if, and only if, at least 75% of the individuals being tested had ratios (of the various pharmacokinetic parameters obtained from the individual results) between the 75% and 125% limits, and the study conducted has the statistical power to detect a 20% difference between the two products. 1 This approach was sound until the arrival of the 90% confidence interval. Later the 75/75 rule lost most of its appeal when it was noted that both the test and reference products each have their own variability, and, therefore, a 90% confidence interval approach was more appropriate for giving some consideration to the differential variability between the test and reference products. 1
90% confidence interval
Westlake 38 was the first to suggest the use of confidence intervals as a BE test to evaluate whether the mean amount of drug absorbed using the test formulation was close to the mean amount absorbed of the reference product. Subsequently, in July 1992, the guidance on Statistical Procedures for Bioequivalence Studies Using a Standard Two-treatment Crossover Design was released by the FDA. It was revised in 2001, and is available as Statistical Approaches to Establishing Bioequivalence (http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ ucm070244.pdf). This is based primarily on average BE (ABE), wherein the average values for the pharmacokinetic parameters were determined for the test and reference products and compared using a 90% confidence interval for the ratio of the averages using a two one-sided t-tests procedure. 39 The ABE approach for BE, however, has limitations for addressing drug switchability, since it focuses only on the comparison of population averages between the test and reference formulations. This concept was really based on the fact that if the ratios of the two pharmacokinetic parameters of clinical interest (such as AUC, C max ) are to be compared, each with their own variability which may or may not be randomly distributed, then such a comparison can truly be done only through a confidence interval approach. This concept is well accepted by almost all regulatory authorities to establish the BE. The general statistical deliverables for a single-dose crossover BE study include summary statistics, ANOVA, 90% confidence interval, ratio analysis, and intra-subject variability in addition to sequence, treatment, and period effects.
Acceptance criteria for bioequivalence
An equivalence approach is generally recommended, which usually relies on i) a criterion to allow the comparison; ii) a confidence interval for the criterion; and iii) a BE limit. Log transformation of exposure measures (C max and AUC) is generally recommended by various regulatory authorities. To compare measures in these studies, data are generally analyzed by using an average BE criterion with some considerations allowed for special category drugs. The general BE profile of generic vs brand product is shown in Figure 4 .
General
To establish BE, the calculated 90% confidence interval should fall within a BE limit of 80% to 125% using logarithm transformed data (adopted since the concentration parameters C max and AUC may or may not be normally distributed). Currently, the BE limits of 80% to 125% have been applied to almost all drug products by regulatory authorities. More detailed information on acceptance criteria for BE is given in Table 14 .
For highly variable drugs
In the context of BE, HVDs are considered to be drugs and drug products exhibiting intra-subject variability greater than 30% coefficient of variation in the pharmacokinetic measures, AUC and/or C max . 39, 40 Due to this high variability, large sample size may be needed in BE studies to give adequate statistical power to meet FDA BE limits, and thus designing BE studies for HVDs is challenging. Consequently development of generic products for HVDs is a major concern for the generic drugs industry. Major regulatory agencies also considered different approaches for evaluating BE of highly variable drugs. [17] [18] [19] 23, 24, 30 From 2004 onward the FDA started looking for alternative approaches to resolve this issue, and eventually found that replicate crossover design and scaled average BE provides a good approach for evaluating the BE of highly variable drugs and drug products as it would effectively decrease sample size, without increasing patient risk. 41 Recently the FDA has issued Method for Statistical Analysis Using the Reference-Scaled Average Bioequivalence Approach for Progesterone Capsules, which Table 9 Regulatory criteria on number of studies required for conducting BA/BE studies [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [30] [31] [32] [33] 
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The basic regulatory considerations for BA/BE studies clearly states how to perform statistical analysis for HVDs, such as progesterone using the replicate crossover design and reference-scaled ABE approach (more information is available at: http://www.fda.gov/downloads/Drugs/ GuidanceCompliance RegulatoryInformation/Guidances/ UCM209294.pdf). The various regulatory agency acceptance criteria for HVDs are given in Table 15 .
For narrow therapeutic index drugs (NTiDs)
NTIDs can be defined as drugs that require therapeutic drug concentration or pharmacodynamic monitoring and/or drugs for which drug product labeling indicates a narrow therapeutic range designation. Perhaps tighter restrictions on these drugs would aid in the establishment of truly bioequivalent drug products within this class. Thus, additional testing and controls may be needed to ensure the quality of these drug products. Table 12 Regulatory "add-on criteria" for conducting BA/BE studies [16] [17] [18] 21, 23, 30 
Regulatory authority Add-on criteria
Europe and Australia it is acceptable to use a two-stage approach when attempting to demonstrate BE. An initial group of subjects can be treated and their data analysed. if BE has not been demonstrated an additional group can be recruited and the results from both groups combined in a final analysis. If this approach is adopted appropriate steps must be taken to preserve the overall type I error of the experiment and the stopping criteria should be clearly defined prior to the study. The analysis of the first stage data should be treated as an interim analysis and both analyses conducted at adjusted significance levels South Africa if the BE study was performed with the appropriate size but BE cannot be demonstrated because of a result of a larger than expected random variation or a relative difference, an add-on subject study can be performed using not less than half the number of subjects in the initial study. Combining is acceptable only if the same protocol was used and preparations from the same batches were used. Add-on designs must be carried out strictly according to the study protocol and standard operating procedures, and must be given appropriate statistical treatment, including consideration of consumer risk Canada As a result of random variation or a larger than expected relative difference, there is no guarantee that the sample size as calculated will pass the standards. if the study is run with the appropriate size and the standards are not met, the sponsor may add more subjects (a minimum of 12). The same protocol should be used (ie, same formulations, same lots, same blood sampling times, a minimum number of 12 subjects). The choice to use this strategy, as with all designs, should be declared and justified a priori. The level of confidence should be adjusted using the Bonferroni procedure. The t-value should be that for P = 0.025 instead of 0.05
Japan
Also for add-on study an additional 10 subjects is recommended along with initial subjects 
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The basic regulatory considerations for BA/BE studies Saudi Arabia Sufficient samples are collected to estimate all the required parameters during absorption and elimination for BE assessment. A sampling period extending to at least 4-5 terminal elimination half-lives of the drug or 4-5 the longest half-live of the pertinent analyte (if more than 1 analyte) is usually sufficient An adequate washout period (eg, more than 5 half-lives of the moieties to be measured) New Zealand
Single-dose blood sampling Sampling should be sufficient to account for at least 80% of the known AUC 0-∞ ; should extend to at least 3 elimination half-lives of the drug; truncated AUC is undesirable except in unavoidable circumstances like the presence of enterohepatic recycling Multiple dose-blood sampling Sampling should be carried out over a full 24-h cycle so that any effects of circadian rhythms may be detected, unless these rhythms can be argued not to have practical significance Urine sampling Adequate number of urine samples should be covered to estimate the amount and excretory rate. For a 24-h study, sampling times of 0-2, 2-4, 4-8, 8-12, and 12-24 h are usually appropriate. where urinary excretion is measured in a single-dose study it is necessary to collect urine for 7 or more half-lives An adequate washout period (at least 3 times the dominating half-life) Abbreviation: LOQ, limit of quantification.
ucm070636.pdf). The regulatory acceptance criterion for NTIDs is given in Table 15 .
Future prospects
The adaptation of the BA/BE concept worldwide for over 20 years has enabled the production and approval of quality generic products through profound scientific, technical, and regulatory advances (especially through replicate designs, application of BCS, scaled average BE) by various approaches to assess BE for various complex and special groups of drugs. This continuing success story of BA/BE is based on the contribution to efficacy, safety, and quality by international regulatory authorities, pharma industry researchers, academic researchers, and indeed the efforts from ICH, WHO, and various international conferences. However, a lot remains to be done, especially to promote global harmonization of BA/BE approaches, which should focus on uniformity, standardization of nomenclature, agreement on general concepts, alternative approaches for locally acting drug products, choice of test procedures, outlier 
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The basic regulatory considerations for BA/BE studies Notes: *For highly variable drugs: a wider difference in C max is considered relevant based on a sound clinical justification. If this is the case the acceptance criteria for C max can be widened to a maximum of 69.84%-143.19%. For this acceptance BE study must be a replicate design where it has been demonstrated that intra-subject Cv for C max of reference drug is .30%. The applicant should justify the calculated intra-subject Cv is a reliable estimate and that it is not the result of outliers and the request for widened interval must be prospectively specified in the protocol. Abbreviations: CV, coefficient of variation; GMR, geometic mean ratio.
challenge, consideration of BE criteria and objectives, all of which reflect regulatory decision-making standards, as well as ensuring product quality over time for both innovator and generic drugs. To achieve these objectives efforts should continue from international health organizations, pharmaceutical industries, researchers, and regulatory authorities to understand and to develop more efficient and scientifically valid approaches to assess BE, and develop generic drugs in a cost-effective manner.
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